EA033861B1 - Пиразины в качестве модуляторов gpr6 - Google Patents

Пиразины в качестве модуляторов gpr6 Download PDF

Info

Publication number
EA033861B1
EA033861B1 EA201691632A EA201691632A EA033861B1 EA 033861 B1 EA033861 B1 EA 033861B1 EA 201691632 A EA201691632 A EA 201691632A EA 201691632 A EA201691632 A EA 201691632A EA 033861 B1 EA033861 B1 EA 033861B1
Authority
EA
Eurasian Patent Office
Prior art keywords
piperidin
isopropylamino
pyrazine
chloro
cyano
Prior art date
Application number
EA201691632A
Other languages
English (en)
Russian (ru)
Other versions
EA201691632A1 (ru
Inventor
Марк Э. Адамс
Джейсон В. Браун
Стефен Хичкок
Мария Хопкинс
Шота Кикучи
Бетти Лэм
Холгер Моненскейн
Холли Рейчард
Хойкай Сунь
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201691632A1 publication Critical patent/EA201691632A1/ru
Publication of EA033861B1 publication Critical patent/EA033861B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
EA201691632A 2014-02-14 2015-02-13 Пиразины в качестве модуляторов gpr6 EA033861B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461940294P 2014-02-14 2014-02-14
PCT/US2015/015841 WO2015123533A1 (en) 2014-02-14 2015-02-13 Pyrazines modulators of gpr6

Publications (2)

Publication Number Publication Date
EA201691632A1 EA201691632A1 (ru) 2017-02-28
EA033861B1 true EA033861B1 (ru) 2019-12-03

Family

ID=52598823

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691632A EA033861B1 (ru) 2014-02-14 2015-02-13 Пиразины в качестве модуляторов gpr6

Country Status (24)

Country Link
US (2) US10000468B2 (enExample)
EP (1) EP3105216B1 (enExample)
JP (1) JP6484640B2 (enExample)
KR (1) KR20160122215A (enExample)
CN (1) CN106103421B (enExample)
AU (1) AU2015218402B2 (enExample)
BR (1) BR112016018418A2 (enExample)
CA (1) CA2939382A1 (enExample)
CL (1) CL2016002043A1 (enExample)
CR (1) CR20160428A (enExample)
DO (1) DOP2016000211A (enExample)
EA (1) EA033861B1 (enExample)
EC (1) ECSP16074207A (enExample)
ES (1) ES2702205T3 (enExample)
GE (1) GEP20186893B (enExample)
IL (1) IL247140B (enExample)
MA (1) MA39337B1 (enExample)
MX (1) MX369857B (enExample)
MY (1) MY184366A (enExample)
PE (1) PE20170245A1 (enExample)
PH (1) PH12016501613B1 (enExample)
UA (1) UA117779C2 (enExample)
WO (1) WO2015123533A1 (enExample)
ZA (1) ZA201606077B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3105216B1 (en) * 2014-02-14 2018-10-10 Takeda Pharmaceutical Company Limited Pyrazine modulators of gpr6
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
KR102317480B1 (ko) 2017-03-23 2021-10-25 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN110520127B (zh) * 2017-03-26 2023-05-16 武田药品工业株式会社 作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺
JOP20180057A1 (ar) * 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
WO2020063760A1 (en) 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
KR20230017787A (ko) * 2020-04-30 2023-02-06 오레곤 헬스 앤드 사이언스 유니버시티 Gpr39 단백질의 길항제

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
WO2002098864A1 (en) * 2001-06-01 2002-12-12 F. Hoffmann-La Roche Ag Pyrimidine, triazine and pyrazine derivatives as glutamate receptors
WO2004054617A1 (ja) * 2002-12-13 2004-07-01 Kyowa Hakko Kogyo Co., Ltd. 中枢疾患の予防および／または治療剤
WO2005079802A1 (en) * 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
US20060199828A1 (en) * 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
WO2014028479A1 (en) * 2012-08-13 2014-02-20 Envoy Therapeutics, Inc. Quinoxaline derivatives as gpr6 modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563142A (en) * 1989-12-28 1996-10-08 The Upjohn Company Diaromatic substituted compounds as anti-HIV-1 agents
WO2001062765A2 (en) * 1999-02-26 2001-08-30 Arena Pharmaceuticals, Inc. Small molecule modulators of g protein-coupled receptor six
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
NZ520484A (en) 2000-02-16 2005-03-24 Neurogen Corp Substituted arylpyrazines that are modulators of CRF (corticotropin releasing factor) receptor and methods of treatment using them
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EA006707B1 (ru) 2002-03-13 2006-02-24 Янссен Фармацевтика Н. В. Сульфонилпроизводные в качестве новых ингибиторов гистон-деацетилазы
CN101693697A (zh) 2003-07-30 2010-04-14 泽农医药公司 哌嗪衍生物和它们作为治疗剂的用途
US20050070718A1 (en) * 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
ATE458730T1 (de) 2004-04-13 2010-03-15 Icagen Inc Polycyclische pyrazine als kaliumionenkanal- modulatoren
GB0414438D0 (en) * 2004-06-28 2004-07-28 Syngenta Participations Ag Chemical compounds
BRPI0611439A2 (pt) 2005-05-13 2010-09-08 Lexicon Pharmaceuticals Inc compostos multicìclicos e métodos para uso dos mesmos
WO2007044085A2 (en) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
US8495335B2 (en) * 2006-06-16 2013-07-23 Raytheon Company Data translation system and method
AU2009271414A1 (en) 2008-06-20 2010-01-21 Metabolex, Inc. Aryl GPR119 agonists and uses thereof
WO2011139489A2 (en) 2010-04-27 2011-11-10 Calcimedica Inc. Compounds that modulate intracellular calcium
MX2012013127A (es) 2010-05-13 2012-11-30 Amgen Inc Compuestos heteroariloxiheterociclilo como inhibidores pde10.
SG185515A1 (en) * 2010-05-13 2012-12-28 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
US10252984B2 (en) * 2011-10-27 2019-04-09 Mayo Foundation For Medical Education And Research Inhibiting G protein coupled receptor 6 kinase polypeptides
TR201911140T4 (tr) 2013-10-21 2019-08-21 Merck Patent Gmbh Btk inhibitörleri olarak heteroaril bileşikleri ve bunların kullanımları.
EP3105216B1 (en) * 2014-02-14 2018-10-10 Takeda Pharmaceutical Company Limited Pyrazine modulators of gpr6

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
WO2002098864A1 (en) * 2001-06-01 2002-12-12 F. Hoffmann-La Roche Ag Pyrimidine, triazine and pyrazine derivatives as glutamate receptors
WO2004054617A1 (ja) * 2002-12-13 2004-07-01 Kyowa Hakko Kogyo Co., Ltd. 中枢疾患の予防および／または治療剤
WO2005079802A1 (en) * 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
US20060199828A1 (en) * 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
WO2014028479A1 (en) * 2012-08-13 2014-02-20 Envoy Therapeutics, Inc. Quinoxaline derivatives as gpr6 modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LACIVITA ENZA; LEOPOLDO MARCELLO: "SELECTIVE AGENTS FOR SEROTONIN(2C)(5-HT2C) RECEPTOR", CURRENT TOPICS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD.HILVERSUM, NL, vol. 6, no. 18, 1 January 2006 (2006-01-01), NL, pages 1927 - 1970, XP009085750, ISSN: 1568-0266, DOI: 10.2174/156802606778522168 *

Also Published As

Publication number Publication date
DOP2016000211A (es) 2016-10-16
BR112016018418A2 (pt) 2017-08-08
IL247140A0 (en) 2016-09-29
IL247140B (en) 2020-02-27
PH12016501613A1 (en) 2017-02-06
EP3105216A1 (en) 2016-12-21
CR20160428A (es) 2017-04-04
CN106103421B (zh) 2019-04-09
CL2016002043A1 (es) 2017-02-17
JP2017509601A (ja) 2017-04-06
WO2015123533A1 (en) 2015-08-20
EP3105216B1 (en) 2018-10-10
AU2015218402B2 (en) 2019-07-11
AU2015218402A1 (en) 2016-09-15
MX369857B (es) 2019-11-25
JP6484640B2 (ja) 2019-03-13
MY184366A (en) 2021-04-01
US10000468B2 (en) 2018-06-19
EA201691632A1 (ru) 2017-02-28
US10273225B2 (en) 2019-04-30
CN106103421A (zh) 2016-11-09
ECSP16074207A (es) 2017-09-29
US20170174659A1 (en) 2017-06-22
CA2939382A1 (en) 2015-08-20
UA117779C2 (uk) 2018-09-25
ZA201606077B (en) 2018-11-28
PE20170245A1 (es) 2017-03-30
US20180258073A1 (en) 2018-09-13
GEP20186893B (en) 2018-09-10
PH12016501613B1 (en) 2021-10-01
KR20160122215A (ko) 2016-10-21
ES2702205T3 (es) 2019-02-27
MA39337A1 (fr) 2017-10-31
MA39337B1 (fr) 2019-11-29
MX2016010529A (es) 2016-10-31

Similar Documents

Publication Publication Date Title
EA033861B1 (ru) Пиразины в качестве модуляторов gpr6
AU2014368992B2 (en) Tetrahydropyridopyrazines modulators of GPR6
WO2014120800A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2014151630A2 (en) Compounds and compositions for the treatment of parasitic diseases
TW201639834A (zh) 新吡啶陽離子化合物
US10597392B2 (en) Tetrahydropyridopyrazines as modulators of GPR6
CA3178347A1 (en) N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as sstr4 agonists
CN121002004A (zh) 取代的噻吩稠合衍生物、包含其的组合物及其作为药物的用途
HK1232522A1 (en) Pyrazine modulators of gpr6
HK1232522B (en) Pyrazine modulators of gpr6
JP2019189573A (ja) 縮合複素環および縮合炭素環誘導体を含有する、疼痛の治療および／または予防用医薬組成物